Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Pacira BioSciences's ebitda for the twelve months ending Jun 30, 2026 was $105.03M. For fiscal 2025 it was $110.21M, up 1935.7% from the year before. Over ten years it grew 18.1% a year on average. The highest annual figure on record is $163.25M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.21M | +1935.7% |
| FY2024 | Dec 31, 2024 | $5.41M | -96.7% |
| FY2023 | Dec 31, 2023 | $163.25M | +7.7% |
| FY2022 | Dec 31, 2022 | $151.53M | +27.9% |
| FY2021 | Dec 31, 2021 | $118.47M | +78.8% |
| FY2020 | Dec 31, 2020 | $66.26M | +120.4% |
| FY2019 | Dec 31, 2019 | $30.06M | +3.4% |
| FY2018 | Dec 31, 2018 | $29.08M | – |
| FY2017 | Dec 31, 2017 | -$11.10M | – |
| FY2016 | Dec 31, 2016 | -$19.11M | -191.3% |
| FY2015 | Dec 31, 2015 | $20.93M | +329.8% |
| FY2014 | Dec 31, 2014 | $4.87M | – |
| FY2013 | Dec 31, 2013 | -$47.54M | – |
| FY2012 | Dec 31, 2012 | -$43.65M | – |
| FY2011 | Dec 31, 2011 | -$34.79M | – |
| FY2010 | Dec 31, 2010 | -$18.64M | – |
| FY2009 | Dec 31, 2009 | -$24.40M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $25.56M | -28.6% |
| Q1 FY2026 | Mar 31, 2026 | $28.23M | +21.9% |
| Q4 FY2025 | Dec 31, 2025 | $23.68M | -48.5% |
| Q3 FY2025 | Sep 30, 2025 | $27.55M | – |
| Q2 FY2025 | Jun 30, 2025 | $35.82M | -24.0% |
| Q1 FY2025 | Mar 31, 2025 | $23.16M | -26.8% |
| Q4 FY2024 | Dec 31, 2024 | $45.95M | -11.0% |
| Q3 FY2024 | Sep 30, 2024 | -$119.27M | -429.9% |
| Q2 FY2024 | Jun 30, 2024 | $47.10M | -20.1% |
| Q1 FY2024 | Mar 31, 2024 | $31.64M | +91.6% |
| Q4 FY2023 | Dec 31, 2023 | $51.65M | +151.8% |
| Q3 FY2023 | Sep 30, 2023 | $36.15M | -12.9% |
| Q2 FY2023 | Jun 30, 2023 | $58.93M | +13.1% |
| Q1 FY2023 | Mar 31, 2023 | $16.51M | -55.9% |
| Q4 FY2022 | Dec 31, 2022 | $20.51M | +18.7% |
| Q3 FY2022 | Sep 30, 2022 | $41.49M | +11.6% |
| Q2 FY2022 | Jun 30, 2022 | $52.10M | +31.1% |
| Q1 FY2022 | Mar 31, 2022 | $37.43M | +54.1% |
| Q4 FY2021 | Dec 31, 2021 | $17.28M | -27.5% |
| Q3 FY2021 | Sep 30, 2021 | $37.16M | +64.0% |
| Q2 FY2021 | Jun 30, 2021 | $39.74M | – |
| Q1 FY2021 | Mar 31, 2021 | $24.29M | +10.8% |
| Q4 FY2020 | Dec 31, 2020 | $23.84M | +250.4% |
| Q3 FY2020 | Sep 30, 2020 | $22.66M | +182.6% |
| Q2 FY2020 | Jun 30, 2020 | -$2.16M | -120.4% |
| Q1 FY2020 | Mar 31, 2020 | $21.92M | +368.4% |
| Q4 FY2019 | Dec 31, 2019 | $6.80M | -58.3% |
| Q3 FY2019 | Sep 30, 2019 | $8.02M | +6.2% |
| Q2 FY2019 | Jun 30, 2019 | $10.56M | +12.4% |
| Q1 FY2019 | Mar 31, 2019 | $4.68M | – |
| Q4 FY2018 | Dec 31, 2018 | $16.31M | +34.6% |
| Q3 FY2018 | Sep 30, 2018 | $7.55M | – |
| Q2 FY2018 | Jun 30, 2018 | $9.39M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.18M | – |
| Q4 FY2017 | Dec 31, 2017 | $12.12M | +1417.3% |
| Q3 FY2017 | Sep 30, 2017 | -$211.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.07M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.95M | – |
| Q4 FY2016 | Dec 31, 2016 | $799.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.59M | – |
See a number that looks wrong?